Alice Zhang
Co-founder and CEO @ Verge Genomics
San Francisco, United States
Alice Zhang is a seed investor at Verge Genomics in San Francisco focused on Biotechnology and Health Care. CEO and Co-founder at Verge Genomics; Angel Investor in Tech-Enabled Bio
- Total investments:
- 15
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Alice Zhang invests in
Stages Alice Zhang invests in
Countries Alice Zhang invests in
Round sizes
Round size
- Seed
- $120k–$5.9M
- Series A
- $12M–$30M
Investment Focus
Industry
- Biotechnology 8 (53%)
- Health Care 7 (47%)
- Therapeutics 4 (27%)
- Medical 3 (20%)
- Pharmaceutical 3 (20%)
Stage
- Seed 9 (60%)
- Series A 5 (33%)
- Pre-Seed 1 (7%)
Country
- United States 11 (73%)
- United Kingdom 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ochre Bio
|
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $30M / Series A / Oct 10, 2022 | |
Arpeggio Bio
|
Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work. | $17M / Series A / Sep 07, 2022 | |
Encellin
|
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California. | $5.9M / Seed / Aug 05, 2021 | |
Osmind
|
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-based medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org. | $15M / Series A / Jul 01, 2021 | |
HumanFirst
|
HumanFirst accelerates the adoption of patient-centered clinical trials using precision digital measures (e.g., digital biomarkers and eCOA).At HumanFirst, we offer a precision measures platform - the world’s largest AI-powered SaaS platform trusted to improve human outcomes. We provide insights, intelligence, and accuracy with validated evidencedata to precisely guide and accelerate human-centric drug development. Twenty-two of the 25 largest pharmaceutical companies in the world have used the HumanFirst platform to evaluate and enable the deployment of digital health technologies (DHTs). | $12M / Series A / May 31, 2021 | |
Multiply Labs
|
Multiply Labs manufactures personalized pharmaceutical capsules that are tailor-made to the unique needs of each patient. Multiply Labs’ product is enabled by the combination of pharmaceutical science with robotics technology. The company has built and operates a unique robotic pharmaceutical manufacturing facility. Multiply Labs is the firstcompany ever to bring to the market 3D printed capsules. | $20M / Series A / Apr 14, 2021 | |
64x Bio
|
A comprehensive platform and product suite for advanced therapeutics. | $4.5M / Seed / Nov 16, 2020 | |
|
Osmind
|
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-based medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org. | $2M / Seed / Oct 14, 2020 | |
|
Arpeggio Bio
|
Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work. | $3.2M / Seed / Jan 15, 2020 | |
|
HumanFirst
|
HumanFirst accelerates the adoption of patient-centered clinical trials using precision digital measures (e.g., digital biomarkers and eCOA).At HumanFirst, we offer a precision measures platform - the world’s largest AI-powered SaaS platform trusted to improve human outcomes. We provide insights, intelligence, and accuracy with validated evidencedata to precisely guide and accelerate human-centric drug development. Twenty-two of the 25 largest pharmaceutical companies in the world have used the HumanFirst platform to evaluate and enable the deployment of digital health technologies (DHTs). | $2.9M / Seed / Nov 12, 2019 | |
| See all 15 investments → | |||
Co-Investors
About Verge Genomics
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created abreakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.
Verge Genomics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alice Zhang
Co-founder and CEO
|
|||
Carla Leibowitz
Chief Business Officer
|
|||
Emily Ripka
Vice President of Product and Engineering
|
|||
Irene Choi
Director, Drug Discovery
|
|||
Jane Rhodes
Chief Business Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Alice Zhang invest in?
Alice Zhang invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alice Zhang's check size?
Alice Zhang typically joins rounds of $120k–$5.9M at Seed and $12M–$30M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alice Zhang participates in.
When did Alice Zhang last invest?
The most recent investment recorded for Alice Zhang closed in Oct 2022. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
